Seizure Prophylaxis for Intracranial Hemorrhage
Routine seizure prophylaxis is NOT recommended for patients with intracranial hemorrhage, whether traumatic or spontaneous, as the evidence shows no benefit in preventing seizures and may actually worsen functional outcomes.
Key Distinction: Traumatic vs. Spontaneous ICH
The approach differs slightly based on etiology, though both converge on avoiding routine prophylaxis:
For Traumatic Brain Injury with ICH
Do not use routine antiepileptic drugs for primary prevention of post-traumatic seizures 1. The 2018 severe TBI guidelines provide a Grade 2- recommendation against prophylactic antiseizure medications for both early (within 7 days) and delayed seizures 1. This recommendation is based on 11 clinical trials involving nearly 2,800 patients that showed:
- No significant effect in preventing early or delayed post-traumatic seizures
- Increased side effects with phenytoin 1
- Potential worsening of neurological outcomes 1
The most recent 2024 Neurocritical Care Society guidelines for moderate-severe TBI echo this, stating that ASM or no ASM may be used (weak recommendation, low quality evidence), but if used, choose levetiracetam over phenytoin for ≤7 days only 2.
For Spontaneous Intracerebral Hemorrhage
Avoid prophylactic antiseizure medications in spontaneous ICH 3. The 2025 Neurocritical Care Society guidelines specifically recommend against prophylactic ASM use based on meta-analyses showing:
- No reduction in early or late seizures
- Increased adverse events
- Higher relative risk of poor functional outcomes at 90 days 3
The 2022 AHA/ASA Stroke guidelines similarly found that prophylactic antiseizure drugs were not associated with preventing early (<14 days) or long-term seizures, and specific cognitive domains might be negatively affected 4.
When to Consider Treatment (Not Prophylaxis)
Active Seizure Suspicion
Treat seizures when they occur, not prophylactically. Consider continuous EEG monitoring for at least 24-48 hours in patients with 4:
- Impaired or fluctuating consciousness out of proportion to brain injury
- No clear rhythmic movements but clinical suspicion remains high
- 94% of electrographic seizures detected by 48 hours of monitoring
Specific High-Risk Scenarios Where Prophylaxis Might Be Considered
The evidence suggests prophylaxis could be considered (though still not strongly recommended) in 1:
- Chronic subdural hematoma
- Past history of epilepsy
- Recent craniectomy (identified as risk factor for early post-traumatic seizures)
If you choose to use prophylaxis in these scenarios: use levetiracetam, NOT phenytoin, due to better tolerance 1.
Duration If Prophylaxis Is Used
Maximum 7 days 2, 3. Longer duration is associated with:
- Worse cognitive outcomes
- Increased adverse events
- No additional seizure prevention benefit
Common Pitfalls to Avoid
Don't automatically give prophylaxis based on GCS alone: Even in severe TBI (GCS ≤8), routine prophylaxis is not recommended 1
Don't use phenytoin: If prophylaxis is chosen despite guidelines, levetiracetam has fewer side effects and better tolerance 1, 2, 3
Don't continue beyond 7 days: Risk scores like CAVE can estimate late seizure risk but should NOT guide continuation of antiepileptic drugs 4
Don't confuse treatment with prophylaxis: Treating active seizures is reasonable; preventing seizures that haven't occurred is not supported 4
The Evidence Landscape
The evidence consistently shows across multiple high-quality guidelines from 2018-2025 that prophylactic antiseizure medications:
- Do not prevent early seizures (within 7-14 days)
- Do not prevent late seizures (>14 days)
- May worsen functional and cognitive outcomes
- Increase adverse events
This represents a shift from older practice patterns, with the Cochrane 2015 meta-analysis (which favored phenytoin) being superseded by more recent evidence showing no benefit and potential harm 1, 2, 3.